Navigation Links
Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimer's Disease Through the PI3k-Akt Pathway
Date:7/18/2013

TACOMA, Wash., July 18, 2013 /PRNewswire/ -- On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational product, RNS60, impacts Alzheimer's Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio's novel nanotechnology platform.

Data presented at the conference demonstrated RNS60's ability to prevent memory loss and improve learning through the PI3k-pAKT pathway.  Additionally, RNS60 upregulates critical genes associated with neuronal plasticity.  These genes play a key role in healthy neurotransmitter and synaptic function, foundational activities of the brain. 

Defining RNS60's activity against these genes is an important link between the significant therapeutic activity demonstrated by RNS60 in mouse and cellular models where RNS60 prevented beta-amyloid induced cell death and tau-neurofibrillary tangles – the most common hallmarks of Alzheimer's disease.

"The ability to define RNS60's biological activity to these plasticity associated genes and the PI3k-pAKT-CREB-BDNF pathway is an important event for the company," said Dr. Richard Watson, Revalesio's Chief Science Officer.  "We have a large and expanding data set on RNS60's ability to reduce inflammation, and these findings are a significant advancement in our understanding of how RNS60 may be a treatment for neuro-degenerative diseases."

These plasticity associated genes and associated pathways have long been targets for drug developers, but Revalesio's approach through its charge-stabilized nanostructure technology provides a new paradigm for treating Alzheimer's disease.  Revalesio and its research partners at Rush University Medical Center have submitted the data for publication. 

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects voltage-sensing membrane-bound proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases. RNS60 has successfully completed Phase I safety studies and is advancing into Phase II clinical trials.

About Revalesio Corporation
Revalesio is a pioneering-clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Jesse Thomas
253-926-5567
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Revalesio Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
2. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the AT&T National
3. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
4. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
5. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
6. Pharma IQ Presents the Latest Trends in Clinical Trial Supply
7. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
8. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
9. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
10. Bluestar Silicones Presents Elastomer Solutions At Medical Design And Manufacturing (MD&M) East Show
11. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):